ARTICLE | Clinical News
Xenova completes Phase IIa XR9576/paclitaxel trial
March 7, 2000 8:00 AM UTC
Xenova, (LSE:XEN; XNVA) said its Phase IIa U.K. study in 12 patients with ovarian cancer treated with Taxol paclitaxel and XEN's XR9576 multi-drug resistance compound, confirmed interim positive pharm...